CAMBRIDGE, Mass. August 4, 2022 – Apnimed, a clinical-stage pharmaceutical company focused on developing oral pharmacologic treatments to address obstructive sleep apnea (OSA) and related disorders, announced today the company will be participating in the upcoming...
– Additional Phase 2b data evaluating AD109 as potential treatment for OSA anticipated in Q3 2022 – AD109 Phase 3 development program expected to be initiated in late 2022 CAMBRIDGE, Mass. June 28, 2022 – Apnimed, a clinical-stage pharmaceutical company focused on...
CAMBRIDGE, Mass. June 16, 2022 – Apnimed, a clinical-stage pharmaceutical company focused on developing oral pharmacologic treatments to address obstructive sleep apnea (OSA) and related disorders, announced today that Ruoxi (Rosy) Hu, Ph.D., from Morningside...